Investors
News Releases
- April 3, 2023Annovis Bio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- March 22, 2023ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES
- February 8, 2023Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
- February 1, 2023Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
- January 25, 2023ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
- January 6, 2023Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team
- November 8, 2022Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update
- October 20, 2022Annovis Bio to Present at the 2022 ThinkEquity Investor Conference
- October 11, 2022Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease
- October 6, 2022Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top